Bio-Path Holdings Inc BPTH
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.11
- Bid/Ask
- $0.00 / $0.05
- Shares Outstanding
- 50.30M
- Market Cap
- $2,802.65
- Volume/Avg
- 3,004 / 44,541
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.biopathholdings.com
Valuation
|
Metric
|
BPTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BPTH
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.07 |
Interest Coverage | −66.34 |
Quick Ratio
BPTH
Profitability
|
Metric
|
BPTH
|
|---|---|
Return on Assets (Normalized) | −514.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BPTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%N<<#YF | LOCK|!V%Ck | $129B | |||
| Moderna Inc
MRNA
| LOCK|%&>k?xG | LOCK|?c | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|z<W$vMp | LOCK|>dHw | $77B | |||
| argenx SE ADR
ARGX
| LOCK|c#@glL | LOCK|Dx | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|C!q%q# | LOCK|^lv | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|M>cs#>F | LOCK|bHps> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&^%k&!@x | LOCK|dXPkn | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|NWJldV | LOCK|^L | $24B | |||
| Incyte Corp
INCY
| LOCK|xX!tf@B | LOCK|M?< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|FQLR$K | LOCK|!! | $14B |
United States